MAY 24, 2019 04:11 PM PDT

First PI3K Inhibitor for Breast Cancer

WRITTEN BY: Nouran Amin

The U.S. Food and Drug Administration has approved Piqray (alpelisib) tablets, to be used in conjunction with FDA-approved endocrine therapy fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer.

“Piqray is the first PI3K inhibitor to demonstrate a clinically meaningful benefit in treating patients with this type of breast cancer. The ability to target treatment to a patient’s specific genetic mutation or biomarker is becoming increasingly common in cancer treatment, and companion diagnostic tests assist oncologists in selecting patients who may benefit from these targeted treatments,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.

“For this approval, we employed some of our newer regulatory tools to streamline reviews without compromising the quality of our assessment. This drug is the first novel drug approved under the Real-Time Oncology Review pilot program. We also used the updated Assessment Aid, a multidisciplinary review template that helps focus our written review on critical thinking and consistency and reduces time spent on administrative tasks.”

It’s important to note that metastatic breast cancer is breast cancer that has reached to other organs in the body most notably the bones, lungs, liver or brain. When breast cancer is hormone-receptor-positive, patients receive anti-hormonal endocrine therapy either alone or in combination with other medicines.

Piqray is a Trademark of the biopharmaceutical company, Novartis

With the efficacy of Piqray and fulvestrant, it can significantly prolong progression-free survival in patients whose tumors had PIK3CA mutation.

Some common side-effects of Piqray include high blood glucose levels, an increase in creatinine, diarrhea, rash, decrease in white blood cell count in the blood, elevated liver enzymes, nausea, fatigue, low red blood cell count, increase in pancreatic enzymes, decreased appetite, stomatitis, vomiting, weight loss, low calcium levels, and hair loss.

Source: FDA

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 12, 2019
Neuroscience
DEC 12, 2019
Can CRISPR Technology Treat Alzheimer's?
New drugs that seek to treat Alzheimer’s disease (AD) have a 99.6% failure rate. This makes it the only disease in the top 10 causes of death that ca...
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
Therapeutic Targets Inflammation Associated with Genetic Heart Disease
Often times when young athletes collapse during the game it is due to sudden cardiac death as a result of the inherited arrhythmogenic cardiomyopathy (ACM)...
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
Metformin Offers No Muscle Mass Gain for Older Adults
A clinical trial initiated by Researchers at the University of Kentucky began a clinical study to address the long-held hypothesis that metformin, the diab...
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
Converting Wood into Pharmaceutical Compounds
Producing toxic byproducts during the making of pharmaceuticals remains a challenge in the drug manufacturing industry. Normally, increased masses of flamm...
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
Investigating a common therapeutic in ADHD treatment
Attention-Deficit Hyperactivity Disorder (ADHD) is a widespread condition with variable underlying causes. A common therapeutic, called methylphenidate, se...
DEC 12, 2019
Genetics & Genomics
DEC 12, 2019
New Way to Determine What Our Genes Do
Geneticists at the University of Virginia (UVA) School of Medicine have developed a new way to determine what our genes do. This will not only allow scient...
Loading Comments...